Reconciliations and other explanations of those non-GAAP financial measures can be found in today's press release and in the earnings supplement, each of which are available on the company's IR site.

Commercial Cell and Gene Therapy Revenue -- $9.1 million, up 26% year over year, reflecting growth in therapies supported.

Nebius Group remains a top neocloud pick, with a bullish rating and 42-138% upside potential over two years. Click to read my ...

Operating results in Q4 were adversely affected by a RMB 66 million one-off provision related to a potentially non-recoverable broadcaster receivable from 2021, leading to a non-GAAP operating loss ...

Gen Z leads the way with investing their refunds (33%), but most (63%) still say they don’t know enough about registered accounts TORONTO, May 4, 2026 /CNW/ – With tax refund season ...

Maritime transportation company Matson (NYSE:MATX) in Q1 CY2026, with sales falling 3.1% year on year to $757.8 million. Its ...

Dr Lal PathLabs share price surged up to 20% to hit upper circuit after Q4FY26 results, with revenue rising 16.6% YoY and ...

Q1 2026 Earnings Call April 30, 2026 2:00 AM EDTCompany ParticipantsJoahnna Soriano - Head of Investor Relations & ...

Running Performance Max alongside Standard Shopping gives advertisers the control, visibility, and reach needed to drive ...

It has been draped in fabric since code enforcement officers came calling — a 14-foot metallic arch bearing the unmistakable ...

CSIS Americas Deputy Director and Senior Fellow Christopher Hernandez-Roy, Joseph Ruelas, and Isabel Teran explore Taiwan’s ...

Nestlé India expects to outperform category growth despite early signs of demand moderation, banking on strong brands, ...